Anabolic therapy for osteoporosis: Parathyroid hormone

Current Rheumatology Reports

Volumn 8, Issue 1, 2006, Pages 63-69

  Cosman, Felicia ^a  

^a HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE;

ARTHRALGIA; BACKACHE; BONE DENSITY; BONE MASS; BONE REMODELING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; ERYTHEMA; FOLLOW UP; HUMAN; HYPERCALCEMIA; INJECTION SITE IRRITATION; LEG CRAMP; MONOTHERAPY; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; REVIEW; TREATMENT DURATION; VERTEBRA FRACTURE; WEAKNESS;

EID: 33750517302     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0028-0     Document Type: Review

References (44)

1. McClung MR, San Martin J, Miller PD, et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005, 165:1762-1768. This study describes biochemical, bone density, clinical, and histomorphometric differences between alendronate and teriparatide and highlight how different mechanisms of action are.
2. Arlot M, Meunier PJ, Boivin G, et al.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253. This study describes biochemical, bone density, clinical, and histomorphometric differences between alendronate and teriparatide and highlight how different mechanisms of action are.
3. Chavassieux PM, Arot ME, Reda C, et al.: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480. This paper describes histomorphometric findings from a subset of subjects enrolled in the Fracture Prevention Trial and highlights the microarchitectural benefits of teriparatide aon cancellous and cortical bone.
4. Boivin GY, Chavassieux PM, Santora AC, et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
5. Roschger P, Rinnerthaler S, Yates J, et al.: Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
6. Hang Y, Zhao JJ, Mitlak BH, et al.: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
7. Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
8. Parfitt AM: PTH and Periosteal Bone Expansion. J Bone Miner Res 2002, 17:1741-1743.
9. Burr D: Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 2005, 3:19-24.
10. Rehman Q, Lang TF, Arnaud CD, et al.: Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003, 14:77-81.
11. Zanchetta JR, Bogado C, Ferretti JL, et al.: Effects of teriparatide [recombinant parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
12. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al.: Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
13. Body J-J, Gaich GA, Scheele WH, et al.: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528-4535.
14. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441. This is the largest teriparatide study (n = 1637 women) and is the source of the fracture efficacy data for teriparatide.
15. Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of rhPTH(1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
16. Vahle JL, Long GG, Sandusky G, et al.: Bone neoplasms in F344 rats given teriparatide [rhPTH (1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.
17. Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18-23.
18. Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
19. Dobnig H, Sipos A, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
20. Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212-5220.
21. Greenspan SL, Marriott TB, Hanley DA, et al.: Full-length PTH prevents first vertebral fracture in postmenopausal women with osteoporosis: results from the TOP study [abstract]. Amer College Rheumatol 2004, Suppl.
22. Greenspan SL, Bone HG, Marriott TB, et al.: Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study [abstract]. J Bone Miner Res 2005, 20(Suppl 1):556.
23. Black DM, Rosen CM, Greenspan S, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215. The PATH study compares PTH, alendronate, and their combination in women who have received no prior therapy.
24. Neer RM, Hayes A, Rao A, et al.: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002, 17:(Supp 1):S135.
25. Cosman F, Nieves J, Woelfert L, et al.: Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998, 13:1051-1055.
26. Cosman F, Nieves J, Zaion M, et al.: Daily and Cylcic parathyroid hormone in women receiving alendronate. N Eng J Med 2005, 353:566-575. This trial evaluated women who had been treated with long term alendronate and showed that PTH can still produce a substantial bone density benefit in these patients. The study also suggests that cyclic PTH therapy is a valid option for future clinical trials.
27. Ettinger B, San Martin J, Crans G, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
28. Lindsay R, Nieves J, Formica C, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
29. Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
30. Roe EB, Sanchez SD, del Puerto GA, et al.: Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - results from a placebo-controlled randomized trial [abstract]. J Bone Miner Res 1999, 12(Suppl 1):S137.
31. Ste-Marie LG, Scheele WH, et al.: Effect of LY333334 [recombinant human parathyroid hormone (1-34), rhPTH(1-34)] on bone density when given to postmenopausal women receiving hormone replacement therapy (HRT) [abstract]. J Clin Endocrinol Metab 2001, 125:39509.
32. Deal C, Omizo M, Schwartz EN, et al.: Raloxifene in combination with teriparatide reduces teriparatide-induced stimulation of bone resorption but not formation in postmenopausal women with osteoporosis. J Bone Miner Res 2004, 19(Suppl 1):S44.
33. Cosman F, Nieves J, Barbuto N, et al.: Parathyroid hormone added to raloxifene and subsequent maintenance of BMD gain with raloxifene alone. J Bone Miner Res 2004, 19(Suppl 1):S98.
34. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
35. Orwoll ES, Scheele WH, Paul S, et al.: The effects of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
36. Kaufman JM, Orwoll E, Goemaere S, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
37. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
38. Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
39. Finkelstein JS, Klibanski A, Arnold AL, et al.: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized, controlled trial. J Am Med Assoc 1998, 280:1067-1073.
40. Lindsay R, Scheele WH, Neer R, et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
41. Kurland ES, Heller SL, Diamond B, et al.: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparitide [human parathyroid hormone (1-34)]. Osteoporo Int 2004, 15:992-997.
42. Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
43. Black DM, Bilezikian JP, Ensrud KE, et al.: One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565. The second year results from the PATH trial confirm in a randomized controlled study that antiresorptive agents are needed after 1 year of PTH to maintain PTH-induced benefits.
44. Cosman F, Nieves J, Zion M, et al.: Effects of PTH(1-34) rechallenge 1 year after the first PTH course in patients on long-term alendronate [abstract]. J Bone Miner Res 2005, 20(Suppl 1):S21.